Takeda Gives Mellinnium Task To Select Best Cancer Drug Candidates
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical is turning over the decision-making about its pipeline of oncology drugs to its American biotech subsidiary, Millennium Pharmaceuticals. Takeda has 15 drugs for treating cancer in clinical trials, but has decided to let Mellinnium draw on its expertise and technology to select the best candidates from among them and speed their development. Takeda is more familiar with hypertension and diabetes drugs, but several best-sellers in those groups face patent expirations next year. (Click here for more - a subscription may be required
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.